14th Nov 2008 09:30
Stock Exchange announcement
FOR release: 9.30am - Friday 14 November 2008
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Purchase of treasury shares
14 November 2008: Celsis International plc, the life sciences products and laboratory services company, today announces that on 14 November 2008 the Company purchased 20,000 of its Ordinary Shares of 5 pence, at a block trading price of 153 pence per share, to be held as Treasury Shares.
Following the purchase, the Company has 590,515 Treasury Shares. Excluding Treasury Shares, the Company has 21,892,528 Ordinary Shares of 5 pence each in issue.
|
Enquiries: |
|
|
Celsis International plc |
Tel: 01223 598 428 |
|
Christian Madrolle, Finance Director and Company Secretary |
|
|
Financial Dynamics |
Tel: 020 7831 3113 |
|
David Yates |
|
|
Jonathan Birt |
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.
Celsis Analytical and Development Services provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from discovery and drug development to analytical chemistry and from biological sciences to stability storage and testing.
Further information can be found on its website at www.celsis.com.
Related Shares:
Celadon Pharmaceuticals